Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (3): 499-505    DOI: 10.31083/j.ejgo.2021.03.2336
Special Issue: Surgery for Gynecological Cancer: Current Evidences and Perspectives
Original Research Previous articles | Next articles
Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery
Mehmet Sait Bakır1, *(), Özer Birge1, Ceyda Karadag1, Selen Doğan1, Hasan Aykut Tuncer1, Tayup Simsek1
1Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, 07070 Antalya, Turkey
Download:  PDF(195KB)  ( 101 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: In the present study, we tried to retrospectively evaluate the clinicopathological characteristics, prognosis and survival of patients with synchronous ovarian and endometrial cancer (SOEC). Material and methods: The data of patients with ovarian cancer who had been admitted to our hospital between February 2006 and March 2019 were retrospectively obtained from the hospital's electronic archive system collected after having obtained the ethics committee approval. Thirty-six patients with epithelial ovarian cancer and simultaneously diagnosed with primary endometrial cancer were included in the study. Patients with non-epithelial ovarian cancer, recurrent, metastatic and metachronous tumor, borderline ovarian tumor, uterine sarcoma and carcinosarcoma, and patients who had not attended regular controls were excluded from the study. Progression-free survival (PFS) and overall survival (OS) were compared using the Kaplan Meier survival analysis. The log rank test was used to test the effect of subgroups on survival. Results: The mean age of the SOEC patients included in the study was 52.05 ± 13.46 years. Of the patients, 8.3% had endometriosis and 16.7% had concurrent adenomyosis. Optimal surgery was seen to have been performed when evaluated with regard to post-operative residual tumor (R0, R1 and R2 61.1%, 33.3% and 5.6%, respectively). The histological grade was Grade 3 in most of the patients (44.4%). When the histology of SOEC patients was examined, endometrioid type was seen to be the most frequent in 18 patients (50%), followed by the serous type in 10 patients (27.8%). The least frequent was clear histology in 2 patients (5.6%). On the other hand, with regard to the endometrial cancer histology of SOEC patients, while the most common type was endometrioid type with 27 patients (75%), serous histological type was seen in 8 patients (22.2%). The five-year progression-free survival (PFS) was 43.6% for all patients, while the overall survival (OS) was 67.1%. The median PFS was 32 months, while the median OS was 89.6 months. In the subgroup analysis was performed as serous/serous histological type with SOEC patients with endometrioid/endometrioid, the median PFS was 53.8 months for the endometrioid/endometrioid type and 11.5 months for the serous/serous type, and it was statistically significant (p: 0.001). In terms of OS for both groups, it was 110.2 and 36.8 months, respectively, and it was statistically significant (p: 0.001). Conclusion: Endometrioid type endometrial cancer is more common than serous in synchronous ovarian and endometrial cancer patients and serous type has a worse prognosis than endometrioid.
Key words:  Synchronous epithelial ovarian cancer      Endometrial cancer      Endometriosis      Survival     
Submitted:  03 December 2020      Revised:  21 December 2020      Accepted:  11 January 2021      Published:  15 June 2021     
*Corresponding Author(s):  Mehmet Sait Bakır     E-mail:  sabakcil@gmail.com

Cite this article: 

Mehmet Sait Bakır, Özer Birge, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek. Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery. European Journal of Gynaecological Oncology, 2021, 42(3): 499-505.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.03.2336     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I3/499

[1] Burak Tatar. Risk of nodal metastasis associated with lymphovascular space invasion in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 850-854.
[2] Jaswinder Chalia, Musse Hussein, Mariya Farooqui, Jordan Mattson, Sally A. Mullany, Molly E. Klein, Boris Winterhoff, Mahmoud A. Khalifa. Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 887-892.
[3] Felix Chan, Cherynne Yuin Mun Johansson. Single-site robotic-assisted hysterectomy and sentinel lymph node mapping for low-risk endometrial cancer: surgical technique and preliminary outcomes[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 966-972.
[4] Englert-Golon Monika, Słopień Radosław, Smolarek Natalia, Burchardt Bartosz, Sajdak Stefan. Synchronous ovarian, endometrial and cervical cancer—case report[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1093-1094.
[5] Laura Baquedano Mainar, Javier Navarro Sierra, Leticia Alvarez Sarrado, Yasmina José Gutiérrez, Marta Lamarca Ballestero, Patricia Rubio Cuesta, Ana C. Ruiz Peña, Andrea Espiau Romera. Clinical and demographic factors in endometrial and ovary carcinoma: synchronous carcinoma vs stage IIIA endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 643-648.
[6] Reem D. Mahmood, Robert D. Morgan, Tine Descamps, Claire Mitchell, Jurjees Hasan, Nerissa Mescallado, Lisa Barraclough, Kate Haslett, Jacqueline Livsey, Emma J. Crosbie, Richard J. Edmondson, Gordon C. Jayson, Andrew R. Clamp. Sequential chemotherapy-radiotherapy as adjuvant treatment of high-risk endometrial carcinoma: a retrospective review of the Manchester experience[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 673-681.
[7] Woraphot Chaowawanit, Vicki Campbell, Emily Wilson, Naven Chetty, Lewis Perrin, Nisha Jagasia, Sinead Barry. Retrospective review of sentinel lymph node mapping in endometrial cancer using indocyanine green and near infra-red fluorescence imaging during minimally invasive surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 694-702.
[8] Hao Lin, Hung-Chun Fu, Fu-Tsai Kung, Yu-Jen Chen, Chan-Chao Chang Chien, Chen-Hsuan Wu, Ching-Chou Tsai, Yu-Che Ou. A comparison of laparoscopic and open surgery for early stage endometrial cancer with analysis of prognostic factors: a propensity score matching study[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 703-710.
[9] Tomoko Sakamoto Taniguchi, Shinichi Komiyama, Masaru Nagashima, Mineto Morita. Characteristics of microsatellite instability-high gynecologic cancer and efficacy of pembrolizumab: a single-institution experience[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 752-756.
[10] Erdem Cubukcu, Ahmet Bilgehan Sahin, Fatma Oz Atalay, Birol Ocak, Mine Ozsen, Candan Demiroz Abakay, Kemal Ozerkan, Ulviyya Hasanzade, Merve Mesohorli, Adem Deligonul, Hakan Ozan, Turkkan Evrensel. The Ki-67 index and neutrophile-lymphocyte ratio are prognostic factors in patients with low-risk endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 775-781.
[11] Ana Carolinne da Silva, Millena Prata Jammal, Renata Margarida Etchebehere, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 782-787.
[12] Nikolaos Giannakopoulos, Ivana Virijevic, Merit Kullinger. Isolated vulvar metastasis after robot-assisted laparoscopic hysterectomy for low grade, early stage endometrial cancer: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 418-424.
[13] Shahzarul Fazril Lin, Zainab Yahaya, Nuraini Ramli, Habibah Abdul Hamid. Synchronous endometrial and ovarian carcinoma (SEOC): case series and literature review[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 434-440.
[14] Sahin Lacin, Gozde Elif Tasar, Alp Usubutun, Zafer Arık, Deniz Yüce, Mehmet Çoşkun Salman, Ayşe Kars. The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 541-547.
[15] Jun Su Park, Heerim Nam, Hyebin Lee, Woo Young Kim. Clinical impact of sarcopenia in patients with uterine cervical cancer treated with radiotherapy[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 567-573.
No Suggested Reading articles found!